SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13D/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13D/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13G - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13D/A - Imago BioSciences, Inc. (0001623715) (Subject)

SC 13G - Imago BioSciences, Inc. (0001623715) (Subject)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

4 - Imago BioSciences, Inc. (0001623715) (Issuer)

SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Michael Arenberg to Chief Operating and Business Officer. Mr. Arenberg is a distinguished biopharmaceutical executive who will be charged with leading strategic operations, investor relations, commercial development and business development of Imago. "I welcome Mike to Imago with great enthusiasm at this important stage of company development," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSc

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company's Board of Directors. "We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of the executive teams of two Boston biotechs that have transitioned from preclinical to successful commercial companies. We look forward to her strategic contributions and guidance as we continue to grow and build PepGen into a leading oligonucleotide therapies company focu

​Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie Keating to its Board of Directors on November 17, 2021. Keating is a seasoned executive, with nearly two decades of her 40-year career in diverse roles within the biopharmaceutical industry. "I am pleased to welcome to Laurie to Imago's Board of Directors as the company continues to grow, following our successful IPO in July," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences. "Laurie brings extensive experience to our Board and we look forward

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago's outstanding shares on a fully diluted basis. All

REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatme

- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks) platelet count in the normal range by week 48 - - 67% (20/30) of patients treated with bomedemstat experienced a decrease in mutant allele frequencies, including JAK2 and CALR – - All 5 patients with baseline loss of heterozygosity (LOH) and follow-up samples showed a reduction in homozygous mutant granulocytes and mutant allele frequencies – -Aligned with FDA on strategy for bomedemstat pivotal

- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - No patients in this Phase 2 study of bomedemstat in advanced myelofibrosis have progressed to acute myeloid leukemia while on treatment - - The Phase 2 study of bomedemstat in advanced myelofibrosis is fully enrolled, with an investigator-sponsored Phase 2 combination study of bomedemstat and ruxolitinib in myelofibrosis currently screening patients - REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical c

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago. Upon the successful closing of the tender offer, stockholders of Imago will receive $36 in cash for each share of Imago common stock validly tendered and not validly withdrawn in the offer, without interest and subject to deduction for any required tax withholding. Following the purchase of shares in the tender offer, Imago will merge with and into a subsidiary of Mer

REDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hemat

Acquisition expands Merck's growing hematology portfolio Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005295/en/ "We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve," said Robert M

- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 - - Start-up activities for Bomedemstat pivotal Phase 3 ET and Phase 2 PV trials continuing to advance - REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "Im

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in two upcoming investor conferences. Details of the events are as follows: H.C. Wainwright 3rd Annual Precision Oncology Conference. Dr. Rienhoff will present on Monday, November 14 at 12:30 pm ET. Stifel Healthcare Conference. Dr. Rienhoff will present on Wednesday, November 16th at 8:00 am ET. Interest

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced two abstracts have been accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 10-13, 2022. ASH 2022 Presentation Details: Oral Presentation Title: "A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)"Session Name: Myeloproliferative Syndromes: Clinical and

Imago BioSciences's (NASDAQ:IMGO) short percent of float has risen 41.79% since its last report. The company recently reported that it has 1.00 million shares sold short, which is 3.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) CymaBay Therapeutics, during October, posted a narrower-than-expected quarterly loss. The company’s stock has a 52-week high of $6.41 .

Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF.   The Phase 2 open-la

Imago BioSciences, Inc. (“Imago”) (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in a poster presentation session during the 64th American Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022. A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30th European Hematology Association Annual Meeting and congress (EHA

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago. Upon the successful closing of the tender offer, stockholders of Imago will receive $36 in cash for each share of Imago common stock validly tendered and not validly withdrawn in the offer, without interest and subject to deduction for any required tax withholding. Following the purchase of shares in the tender offer, Imago will merge with and into a subsidiary of Merc

Imago BioSciences's (NASDAQ:IMGO) short percent of float has fallen 3.48% since its last report. The company recently reported that it has 3.43 million shares sold short, which is 13.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.9 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short

 Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine

Upgrades Barclays upgraded the previous rating for PerkinElmer Inc (NYSE:PKI) from Underweight to Equal-Weight. For the third quarter, PerkinElmer had an EPS of $1.51, compared to year-ago quarter EPS of $2.31. The stock has a 52-week-high of $201.05 and a 52-week-low of $113.46. At the end of the last trading period, PerkinElmer closed at $136.93. JP Morgan upgraded the previous rating for Cloudflare Inc (NYSE:NET) from Underweight to Neutral. Cloudflare earned $0.06 in the third quarter, compared to $0.00 in the year-ago quarter. The stock has a 52-week-high of $132.45 and a 52-week-low of $37.37. At the end of the last trading period, Cloudflare closed at $46.30. JP Morgan upgraded

Within the last quarter, Imago BioSciences (NASDAQ:IMGO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 4 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Imago BioSciences has an average price target of $34.17 with a high of $36.00 and a low of $25.00. Below is a summary of how these 6 analysts rated Imago BioSciences over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative an

Stifel analyst Stephen Willey downgrades Imago BioSciences (NASDAQ:IMGO) from Buy to Hold and raises the price target from $35 to $36.